Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NI-1801 |
Synonyms | |
Therapy Description |
NI-1801 is a bispecific antibody to CD47 and mesothelin, designed to target tumor cells expressing mesothelin and block CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873856). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NI-1801 | NI 1801|NI1801 | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 MSLN Antibody 12 | NI-1801 is a bispecific antibody to CD47 and mesothelin, designed to target tumor cells expressing mesothelin and block CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873856). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |